Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1295 • ACR Convergence 2021
Belimumab Reduces Severe Flares in Systemic Lupus Erythematosus Across Multiple Patient Subgroups: Results of a Large Integrated Analysis
Michelle Petri¹, Norma Lynn Fox², Mathew Gibb³, Tania Gonzalez-Rivera², Anne Hammer², Holly Quasny⁴, Ronald van Vollenhoven⁵ and David Roth², ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²GlaxoSmithKline, Collegeville, PA, ³Veramed Ltd., Twickenham, United Kingdom, ⁴GlaxoSmithKline, Research Triangle Park, NC, ⁵Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands
Background/Purpose: Belimumab (BEL) is a disease-modifying systemic lupus erythematosus (SLE) treatment that inhibits B-lymphocyte stimulator. BEL has demonstrated a consistent efficacy profile across 4 pivotal…
Abstract Number: 1446 • ACR Convergence 2021
Trauma Is Associated with Flares in Systemic Lupus Erythematosus (SLE)
Patricia Katz¹, Kimberly DeQuattro¹, Sarah Patterson², Laura Trupin³, Kamil Barbour⁴, Stephanie Rush¹, Cristina Lanata⁵, Jinoos Yazdany¹ and Maria Dall'Era⁶, ¹University of California San Francisco, San Francisco, CA, ²University of California San Francisco, Pacifica, CA, ³UC San Francisco, San Francisco, CA, ⁴Centers for Disease Control, Atlanta, GA, ⁵University of California San Francisco, Moss Beach, CA, ⁶University of California San Francisco, Corte Madera, CA
Background/Purpose: Daily psychological stress and trauma exposure with or without symptoms of post-traumatic stress disorder have been linked to an increased risk of SLE onset.1,…
Abstract Number: 1489 • ACR Convergence 2021
Identification of Mitochondrial Antigens Targeted by Autoantibodies in Systemic Lupus Erythematosus (SLE)
Yann BECKER¹, Jean-Philippe Gagné², Anne-Sophie Julien³, Tania Lévesque¹, Nadine Gougeard⁴, Vicente Rubio⁴, François-Michel Boisvert⁵, Dominique Jean⁶, Guy Poirier², Paul R Fortin⁷ and Éric Boilard¹, ¹Centre de Recherche ARThrite, Université Laval, Québec City, QC, Canada, ²Centre de Recherche du Centre Hospitalier Universitaire de Québec - Université Laval, Québec City, QC, Canada, ³Département de mathématiques et statistique, Université Laval, Québec, QC, Canada, ⁴Structural Enzymopathology Unit, Instituto de Biomedicina de Valencia, Consejo Superior de Investigaciones Científicas, Valencia, Spain, ⁵Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Anatomy and Cell Biology, Université de Sherbrooke, Sherbrooke, Canada, ⁷CHU de Quebec - Universite Laval, Québec City, QC, Canada
Background/Purpose: Mitochondria are organelles that possess several bacterial features such as a double-stranded genome with hypomethylated CpG islets, formylated proteins, and a double membrane composed…
Abstract Number: 1526 • ACR Convergence 2021
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Chathura Wijewardena¹, Paramarajan Pirinavan¹, Sandy Nasr¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of…
Abstract Number: 1723 • ACR Convergence 2021
Factors Associated with Postpartum Flare in Women with Lupus
Anitha Ramu¹, Maedeh Veyseh¹, Brianna Lally², Shudan Wang³ and Anna Broder⁴, ¹Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine/Montefiore Medical Center, New York, NY, ⁴Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Several prior studies have assessed disease activity in the setting of pregnancy and have shown that certain factors such as thrombocytopenia, systemic lupus erythematosus…
Abstract Number: 1747 • ACR Convergence 2021
BIIB059 Demonstrates Improvement in Joint Manifestations in Participants with Systemic Lupus Erythematosus in Part a of a Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
Ronald van Vollenhoven¹, Richard Furie², Kenneth Kalunian³, Maria Dall'Era⁴, Victoria Werth⁵, Xiaobi Huang⁶, Hua Carroll⁶, Cristina Musselli⁶, Catherine Barbey⁷ and Nathalie Franchimont⁶, ¹Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam Rheumatology Center, Amsterdam, Netherlands, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³UC San Diego, La Jolla, CA, ⁴University of California San Francisco, Corte Madera, CA, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Biogen, Cambridge, MA, ⁷Biogen, Baar, Switzerland
Background/Purpose: Joint involvement, a frequent manifestation of SLE, can be assessed using global lupus disease activity indices (SLEDAI-2K, BILAG-2004) and/or by assessing joint tenderness and…
Abstract Number: 1766 • ACR Convergence 2021
Itolizumab-induced Modulation of Cell Surface CD6 Is a Pharmacodynamic Marker of Drug Activity in SLE Patients
Dalena Chu¹, Leslie Chinn², Jeanette Ampudia¹, Krishna Polu¹, Joel Rothman¹, Maple Fung³, Dolca Thomas⁴, Chaim Putterman⁵, Cherie Ng¹ and Stephen Connelly¹, ¹Equillium, Inc., La Jolla, CA, ²Equillium, Inc., South San Francisco, CA, ³Equillium, Inc., San Diego, CA, ⁴Equillium, Inc., Brooklyn, NY, ⁵Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Itolizumab (ITO) is a novel first-in-class monoclonal antibody (IgG1-k) specific for CD6, a co-stimulatory receptor that is highly expressed on T cells that plays…
Abstract Number: 1937 • ACR Convergence 2021
IL-16 Is Linked to Lupus Nephritis Activity
Andrea Fava¹, Deepak Rao², Chandra Mohan³, Ting Zhang³, Avi Rosenberg¹, Paride Fenaroli⁴, H. Michael Belmont⁵, Peter Izmirly⁶, Robert Clancy⁷, Jose Monroy-Trujillo¹, Derek Fine¹, Arnon Arazi⁸, Celine Berthier⁹, Anne Davidson¹⁰, Judith James¹¹, Betty Diamond¹², Nir Hacohen¹³, David Wofsy¹⁴, Soumya Raychaudhuri², Accelerating Medicines Partership (AMP) RA/SLE Network¹⁵, Jill Buyon⁵, Michelle Petri¹⁶ and The Accelerating Medicines Partnership in RA/SLE¹⁷, ¹Johns Hopkins University, Baltimore, MD, ²Brigham and Women's Hospital, Boston, MA, ³University of Houston, Houston, TX, ⁴Universita` degli Studi di Parma, Parma, Italy, ⁵NYU School of Medicine, New York, NY, ⁶New York University School of Medicine, New York, NY, ⁷NYU Grossman School of Medicine, New York, NY, ⁸Feinstein Institutes for Medical Research, Melrose, MA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Institute of Molecular Medicine, Feinstein Institutes for Medical Research, Manhasset, NY, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²Northwell Health, Manhasset, NY, ¹³Broad Institute, Cambridge, MA, ¹⁴University of California San Francisco, San Francisco, CA, ¹⁵Brigham and Women's Hospital, Everett, MA, ¹⁶Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁷Multiple Institutions, Multiple
Background/Purpose: There is a pressing need to identify novel therapeutic targets in lupus nephritis. Multiomic approaches hold great potential for discovery. We integrated urine proteomics…
Abstract Number: 0089 • ACR Convergence 2021
SARS-CoV-2 Seroprevalence and Seroconversion in a Systemic Lupus Erythematosus Cohort and Comparison to General Population Controls
Hannah Mathew¹, May Choi², Katherine Buhler¹, Ann Clarke¹, Xenia Gukova¹, Francesca Cardwell³ and Marvin Fritzler¹, ¹University of Calgary, Calgary, AB, Canada, ²Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ³University of Waterloo, Waterloo, ON, Canada
Background/Purpose: At the outset of the SARS-CoV-2 pandemic, it was speculated that SLE patients may be at significant risk of developing COVID-19 due to underlying…
Abstract Number: 0326 • ACR Convergence 2021
Apolipoprotein L1 (APOL1) in African-American SLE: Frequency and Clinical Associations
Michelle Petri¹, Romy Kallas², Jessica Li³, Laurence Magder⁴ and Daniel Goldman¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Lankenau Medical Center, Lankenau, PA, ³Johns Hopkins University, Baltimore, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: The APOL1 gene is implicated in induction of TLR3 agonists and interferons as well as in autophagy. Two genetic variants, G1 (2 single nucleotide…
Abstract Number: 0343 • ACR Convergence 2021
Overview of the Childhood Systemic Lupus Erythematosus (cSLE) Cohort in the CARRA Registry
Christine Bacha¹, Anne Dennos², Andrea Knight³, Laura Schanberg⁴, Mary Beth Son⁵, Emily von Scheven⁶, Shahla Amin⁷, Charles Helmick⁸ and Aimee Hersh⁹, ¹Nationwide Children's Hospital, Grandview Heights, OH, ²Duke University, Durham, NC, ³Hospital for Sick Children, Toronto, ON, Canada, ⁴Duke University Medical Center, Durham, NC, ⁵Boston Children's Hospital, Brookline, MA, ⁶University of California San Francisco, San Francisco, CA, ⁷CARRA, Durham, NC, ⁸Centers for Disease Control and Prevention, Atlanta, GA, ⁹University of Utah, Salt Lake City, UT
Background/Purpose: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry is a multi-center, observational registry that collects demographic, clinical, and provider- and patient-reported data from…
Abstract Number: 0473 • ACR Convergence 2021
Disease-Associated Microglia Are Implicated in Neuropsychiatric Manifestations of Systemic Lupus Erythematosus
Hadijat Makinde¹, Shang-Yang Chen¹, Elise Mike², Chaim Putterman², Deborah Winter³ and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Albert Einstein College of Medicine, Bronx, NY, ³Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune syndrome affecting multiple organs, including the brain. Though 50% of patients may experience neuropsychiatric symptoms (NPSLE),…
Abstract Number: 0599 • ACR Convergence 2021
Effectiveness of a Provider Led Intervention on Medication Adherence in an Urban Lupus Clinic
Nancyanne Schmidt¹, Yevgeniya Gartshteyn², Teja Kapoor³, Laura Geraldino⁴, Leila Khalili⁵ and Anca Askanase⁶, ¹New York Presbyterian/Columbia University Medical center, New York, NY, ²Columbia University Medical Center, Glen Rock, NJ, ³Columbia University Irving Medical Center, Leonia, NJ, ⁴New York Presbyterian Hospital - Columbia Campus, New York, NY, ⁵Columbia University Medical Center, New Haven, NY, ⁶Columbia University Medical Center, New York, NY
Background/Purpose: Medication adherence is a difficult charge in SLE. Up to 75% of lupus patients are non-adherent with hydroxychloroquine (HCQ). Pharmacy refill data measured by…
Abstract Number: 0774 • ACR Convergence 2021
The Impact of Patient/Provider Discordance on Changes on Mood and Behavior in Adolescents with Systemic Lupus Erythematosus
Zanab Mian¹, Terrence Calistro², Kimberly Rapoza², Shari Berkowitz², Tamar Rubinstein³, Kathleen Kenney-Riley² and Joyce Hui-Yuen⁴, ¹Cohen Children's Medical Center, New Hyde Park, NY, ²Mercy College, Dobbs Ferry, NY, ³Albert Einstein College of Medicine, White Plains, NY, ⁴Cohen Childrens Medical Center, New Hyde Park, NY
Background/Purpose: Discordance between physicians’ and patients’ perceptions of disease severity can negatively impact treatment and disease outcomes; this has not yet been studied in children…
Abstract Number: 0867 • ACR Convergence 2021
A Proteomic/Transcriptomic Analysis Associates with Subclinical Vascular Disease in Systemic Lupus Erythematosus
Christopher Oliveira¹, Yenealem Temesgen-Oyelakin², Mohammad Naqi³, Nidhi Patel², Philip Parel², Massimo Gadina⁴, Stefania Dell'Orso², Stephen Brooks², Sarthak Gupta⁵, Nehal Mehta⁶, Sarfaraz Hasni³ and Mariana Kaplan³, ¹National Institutes of Health (NIH), Vienna, VA, ²National Institutes of Health (NIH), Bethesda, MD, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁵National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁶NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is associated with enhanced cardiovascular (CV) risk linked to both traditional Framingham risk factors and lupus-specific immune dysregulation. Characterizing an…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].